A wave of gene‑editing studies published this April shows that patients with severe blood disorders are finally seeing lasting, transfusion‑free lives. In China, a team led by Prof. Chen Jia (ShanghaiTech) and collaborators reported in *Nature* the results of a Phase 1 trial using a transformer base editor (tBE) to modify patients’ own CD34+ stem cells. Five β‑thalassemia patients received the edited cells (CS‑101) and, after a median 23‑month follow‑up, all stopped blood transfusions within three weeks. Hemoglobin levels rose to an average of 12.4 g/dL and fetal hemoglobin (HbF) stayed high, while engraftment times for neutrophils and platelets were rapid (16 and 25 days). No deaths, cancers, or unexpected side‑effects were reported. Across the Pacific, three NEJM papers described CRISPR‑Cas12a and base‑editing approaches (reni‑cel and risto‑cel) for sickle cell disease and transfusion‑dependent β‑thalassemia. In a multicenter Phase 1‑2 study, 27 of 28 sickle‑cell patients experienced no painful vaso‑occlusive crises after treatment, and hemoglobin normalized with a surge in HbF. A parallel β‑thalassemia trial showed rapid neutrophil recovery, sustained HbF increase, and complete transfusion independence. Another base‑editing trial (risto‑cel) confirmed durable HbF elevation and a drop in sickle hemoglobin. Together, these studies mark the first clinical successes of precise gene‑editing for anemia‑related disorders, offering a potential cure for tens of thousands of children born each year with β‑thalassemia or sickle cell disease.
Read moreChina’s drug regulator has fast‑tracked 13 innovative medicines to market so far in 2026, covering everything from cancer therapies to diabetes and cholesterol pills. Six of these are first‑in‑class drugs, meaning they work in ways no existing medicine does. One headline‑grabbing approval is BeiGene’s tarlatamab (branded Entedrig), the world’s first bispecific T‑cell engager that targets both DLL3 and CD3, now conditionally cleared for small‑cell lung cancer. The drug is being co‑developed and sold in China by BeiGene and U.S. giant Amgen. The approval surge reflects a broader shift: multinational firms are moving beyond simple licensing deals and forming deeper collaborations with Chinese innovators. Zai Lab, for example, is running a global Phase 3 trial of its own DLL3‑targeted ADC, Zocilurtatug, while supplying the drug to Amgen for joint development. In these models, Chinese companies keep full ownership of their molecules and share clinical expertise, creating a win‑win that speeds up patient access. China’s overseas licensing deals for innovative drugs topped $60 billion in the first quarter alone—almost half of the total expected for the whole year. Industry leaders say Chinese firms still need partners to build overseas sales teams, navigate foreign regulations and set up supply chains. The government’s latest work report also highlighted the push to expand commercial health‑insurance coverage for these cutting‑edge treatments, underscoring the country’s commitment to turning scientific breakthroughs into everyday medicines.
Read moreForeign medical‑device makers are speeding up both product and research localisation in China to stay ahead of a fast‑growing market and rising domestic competition. At the 93rd China International Medical Equipment Fair, Canon Medical’s China chief Katsuya Takao announced that the company now produces its entire line of CT scanners, X‑ray, ultrasound and other imaging equipment locally, and is moving toward making key components in‑house. The push isn’t limited to manufacturing – Chinese R&D teams, working closely with frontline hospitals, are filing patents and launching AI‑driven diagnostic tools that are designed specifically for Chinese patients. Similar moves were seen from Siemens Healthineers and GE Healthcare, where more than 60 % of showcased innovations were born from Chinese labs and 95 % of the hardware was made in China. Highlights included world‑first brain‑computer‑interface devices, dual‑source CT scanners, and AI platforms that can scan multiple organs in a single pass. Companies say the strategy blends high‑end technology with mid‑range models to serve both top‑tier hospitals and community clinics. Canon, celebrating 50 years in China, pledged to keep investing in local production, clinical partnerships and talent development, underscoring that China remains a crucial, long‑term market for global med‑tech innovators.
Read more